| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
1 company
Curt H LaBelle last filed a Form 4 in April 2023, as Director at HYPD. Curt H LaBelle's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 42,236 shares of HYPD. Net of sales, the HYPD filings show accumulation of 27,985 shares.
Curt H LaBelle has 8 Form 4 filings on record from January 2018 to April 2023, across 2 companies: Director at Revelation Biosciences (REVB), 2023; Director at Hyperion Defi (HYPD), 2018–2021.
The 10 reported transactions were 4 option or other derivative awards, 2 stock awards, 2 open-market purchases and 1 other transaction, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $150K and no sales.
The largest open-market purchase was 10,000 shares of HYPD at an average $10.00 on January 29, 2018, about $100K.
Shares as reported in the last Form 4 for each company; the most recent is from April 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.